Rocket Lab’s $266 Million Space Force Deal Can’t Stop a 35% Rout as Iridium Debt Spooks Investors

Rocket Lab shares tumble 35% in 30 days as $266M Space Force contract and $8B Iridium acquisition fail to offset investor fears over $3.6B debt and dilution risk.

The disconnect between corporate achievement and market reception has rarely been starker than at Rocket Lab this month. On July 27, the company secured a $266 million contract with the US Space Force — the largest in its history — only to watch its stock shed nearly 6% in a single session. Over the past 30 days, the shares have tumbled roughly 35%, erasing gains that had been building since the start of the year.

The headline numbers tell a brutal story. The stock closed at €55.30 on Tuesday, down 5.95% on the day, and now sits 58% below the 52-week high of €133.80 reached in late May. The 200-day moving average of €67.39 has been decisively broken, with the current price hovering almost 17% beneath that key institutional benchmark — a textbook signal that the long-term trend has fractured.

Yet beneath the surface, the company’s operational engine is firing on multiple cylinders. The Space Force contract covers up to 18 suborbital missions from a new launch pad at the Pacific Spaceport Complex in Kodiak, Alaska, using the HASTE rocket for missile-defense testing. That follows a separate $190 million hypersonic test-flight deal secured in March, and the June announcement of an $8 billion acquisition of Iridium Communications — a transformative deal that would turn Rocket Lab from a pure-play launch provider into a vertically integrated space conglomerate with recurring satellite revenue.

The market, however, is fixated on the financing side of that Iridium bet. To fund the acquisition, Rocket Lab has taken on a $3.6 billion bridge loan — a heavy debt load for a company with a market capitalization of roughly €44.36 billion that has only recently begun flirting with profitability. Investors are pricing in dilution risk and balance-sheet strain, and no amount of contract wins seems to offset that anxiety for now.

Technical indicators suggest the selling may be approaching exhaustion. The 14-day relative strength index has fallen to 32, edging into oversold territory. Analysts, meanwhile, have barely budged from their bullish stance: the consensus price target stands at €100.52, implying upside of roughly 80% from current levels. That gap between analyst conviction and market action is unusually wide, and it points to a stock caught between a short-term panic and a longer-term thesis that remains intact.

The company’s most critical catalyst is the Neutron rocket, a reusable medium-lift vehicle designed to compete with SpaceX’s Falcon 9. In mid-July, Rocket Lab completed a full-duration, 5.5-minute burn test of the Archimedes engine at NASA’s Stennis facility — a prerequisite for Neutron’s first flight, still targeted for late 2026. Under normal circumstances, such a milestone would be a share-price driver. Instead, it was swallowed by the broader sell-off.

Operationally, the core business continues to strengthen. The order book has swelled to a record $2.2 billion, and first-quarter revenue grew 63.5% year over year. The 30-day volatility reading of nearly 89% underscores just how jittery the market has become, but the underlying metrics suggest a company that is executing on multiple fronts simultaneously.

What makes Rocket Lab’s current predicament so unusual is that both narratives — the operational success story and the balance-sheet cautionary tale — are simultaneously true. The company has transformed from a small-satellite launch startup into a defense contractor, satellite operator, and would-be telecom player in the span of a few quarters. Whether that transformation succeeds or stumbles will hinge on the Iridium integration and the Neutron debut. In the meantime, the stock is being forced to answer a question that no single contract win can resolve: how much debt is too much for a growth story still proving itself?